Ignite Creation Date:
2025-12-25 @ 2:31 AM
Ignite Modification Date:
2026-01-08 @ 7:03 PM
Study NCT ID:
NCT04693234
Status:
COMPLETED
Last Update Posted:
2025-04-27
First Post:
2020-12-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
Sponsor:
BeiGene
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
BGB-A317-A1217-202
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None